<DOC>
	<DOCNO>NCT02570529</DOCNO>
	<brief_summary>Pancreatic ductal adenocarcinoma fourth cause death Western world . About 40 % pancreatic cancer patient diagnose locally advanced unresectable status without distant metastasis . Concurrent chemoradiotherapy ( CCRT ) reasonable treatment modality locally advanced pancreatic cancer . However , several adverse event chemoradiation could lead unfavorable treatment result , include unique gastrointestinal ( GI ) toxicity , ulcer hemorrhage stomach duodenum include radiation field . According study investigator hospital , 45 % locally advanced pancreatic cancer patient treat CCRT suffer GI ulcer , among , 65 % patient experience significant hemorrhage event . Although GI toxicity , study radioprotective agent limited . Albis® newly develop drug comprise ranitidine , bismuth sucralfate . The investigator investigate radioprotective effect Albis® locally advance pancreatic cancer patient treat CCRT .</brief_summary>
	<brief_title>Prevention Upper Gastrointestinal Hemorrhage Using Albis® Patients Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<criteria>Older 20 year old young 80 year old Pathologically confirm pancreatic ductal adenocarcinoma ( metastatic locally advanced stage ) ECOG Performance status ≤2 Scheduled fot concurrent chemoradiation Adequate liver function ( total bilirubin &lt; 1.5 X upper limit normal ( ULN ) , AST ALT &lt; 3 X UNL , alkaline phosphatase &lt; 3 X ULN &lt; 5 x ULN case liver involvement ) Adequate BM function ( WBC ≥ 3,500/µl , absolute neutrophil cell count ≥ 1,500 /µl , platelet count ≥ 100,000/µl ) Not remarkable coagulation profile ( PT &lt; 1.5 international normalize ratio ( INR ) , aPTT &lt; 35 sec ) Subjects give write informed consent give full description study Coexisting malignancy within 5 year , except squamous cell carcinoma basal cell carcinoma skin Evidence distant metastasis , liver , peritoneum brain history receive chemoradiation pancreatic cancer hospital History receiving operation affect anatomy upper gastrointestinal tract Any trouble examination upper endoscopy Evidence GI ulcer ( A1~H2 ) endoscopy start chemoradiotherapy . Use aspirin , antiplatelet agent , anticoagulation agent , NSAIDs , glucocorticoid within 1 week enable stop administration ( include start chemoradiation ) Use PPI , Histamine2 receptor antagonist , antacid , prostaglandin , sucralfate within 2 week enable stop administration Patients unwilling unable provide inform consent , psychiatric problem , drug abuse alcoholism</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Chemoradiotherapy</keyword>
	<keyword>Gastrointestinal toxicity</keyword>
	<keyword>Albis</keyword>
</DOC>